30/06/22
Opyl joins forces with two key patient advocate groups
Opyl has partnered with two leading patient advocate groups in an important move for its flagship trial recruitment program Opin.
“Opyl (ASX: OPL) has announced it has signed partnerships with NeuroEndocrine Cancer Australia and Pancare Foundation, two leading advocates for a large patient community with neuroendocrine and upper GI tract cancers.”
Read the article on Stockhead website: https://stockhead.com.au/health/opyl-joins-forces-with-two-key-patient-advocate-groups/